Last reviewed · How we verify
Loteprednol Etabonate 0.5% Oph Gel
Loteprednol Etabonate 0.5% Oph Gel is a Topical corticosteroid Small molecule drug developed by University of Utah. It is currently FDA-approved for Inflammation and pain following ocular surgery, Seasonal allergic conjunctivitis, Uveitis.
Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Loteprednol etabonate is a topical corticosteroid that suppresses inflammatory responses in the eye by binding to glucocorticoid receptors and inhibiting inflammatory mediator production. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Post-operative inflammation following ocular surgery, Seasonal allergic conjunctivitis.
At a glance
| Generic name | Loteprednol Etabonate 0.5% Oph Gel |
|---|---|
| Sponsor | University of Utah |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Loteprednol etabonate is a soft corticosteroid designed to minimize systemic absorption while providing potent local anti-inflammatory effects in ocular tissues. It reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration. The ester structure allows rapid metabolism to inactive metabolites, reducing the risk of steroid-induced ocular hypertension and other systemic side effects.
Approved indications
- Inflammation and pain following ocular surgery
- Seasonal allergic conjunctivitis
- Uveitis
- Dry eye disease
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Ocular hypertension (elevated intraocular pressure)
- Headache
Key clinical trials
- Loteprednol vs. Prednisolone and Fluorometholone (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol Etabonate 0.5% Oph Gel CI brief — competitive landscape report
- Loteprednol Etabonate 0.5% Oph Gel updates RSS · CI watch RSS
- University of Utah portfolio CI
Frequently asked questions about Loteprednol Etabonate 0.5% Oph Gel
What is Loteprednol Etabonate 0.5% Oph Gel?
How does Loteprednol Etabonate 0.5% Oph Gel work?
What is Loteprednol Etabonate 0.5% Oph Gel used for?
Who makes Loteprednol Etabonate 0.5% Oph Gel?
What drug class is Loteprednol Etabonate 0.5% Oph Gel in?
What development phase is Loteprednol Etabonate 0.5% Oph Gel in?
What are the side effects of Loteprednol Etabonate 0.5% Oph Gel?
What does Loteprednol Etabonate 0.5% Oph Gel target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: University of Utah — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Inflammation and pain following ocular surgery
- Indication: Drugs for Seasonal allergic conjunctivitis
- Indication: Drugs for Uveitis
- Compare: Loteprednol Etabonate 0.5% Oph Gel vs similar drugs
- Pricing: Loteprednol Etabonate 0.5% Oph Gel cost, discount & access